Mesothelioma Drug Pipeline — PatSnap Eureka
Mesothelioma Drug Pipeline: Mesothelin ADC, CAR-T & Checkpoint Combinations
Malignant mesothelioma has a median survival of 8–14 months on standard chemotherapy. A rapidly expanding pipeline of MSLN-targeted biologics and immune checkpoint strategies is redefining the therapeutic landscape — explore the patent and literature signals shaping it.
Why Mesothelin Is the Dominant Actionable Antigen in Mesothelioma
Malignant mesothelioma is a rare, asbestos-associated cancer arising from the mesothelial lining of the pleura and peritoneum. With 2,500–3,000 new cases per year in the United States and median survival of 8–14 months, it remains one of oncology's most therapeutically intractable diseases. The genomic landscape is defined not by druggable oncogene mutations but by the loss of tumor suppressors — CDKN2A (homozygous deletion in ~70% of cases), NF2/merlin (inactivated in ~40%), BAP1, LATS1/2, and TP53 alterations are the dominant genomic events, as characterized by researchers at Brigham and Women's Hospital/Harvard Medical School. These losses activate Hippo and mTOR signaling, creating downstream vulnerabilities.
Mesothelin (MSLN) emerges as the single most prominently featured therapeutic target. As characterized in a review from Nemours Children's Hospital, MSLN is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein overexpressed in the vast majority of MPM patients, expressed at low levels in normal tissues, making it a favorable tumor-associated antigen (TAA) for targeted intervention. MSLN is expressed at high levels in diseased pleura and peritoneum in the majority of MM patients, and soluble MSLN is FDA-approved as a monitoring biomarker. PatSnap's IP analytics platform enables researchers to map the full MSLN patent landscape across ADC, CAR-T, and immunotoxin modalities.
Secondary targets include EGFR (highly overexpressed in MM cell lines), AXL and MET receptor tyrosine kinases (co-expressed in MPM, linked to PI3K/AKT/mTOR pathway activation), PD-1/PD-L1 and CTLA-4 checkpoints (the current approved immunotherapy axis), and emerging targets such as TIGIT, GITR/GITRL, OX40, STAT3, KDM4A, and heparanase.
MSLN-Targeted and Checkpoint Approaches Across the Pipeline
From FDA-approved checkpoint combinations to preclinical ADCs and CAR-T trials, the mesothelioma pipeline spans multiple modalities with converging strategies on the MSLN antigen and immunosuppressive TME.
Mesothelin-Targeted Antibody-Drug Conjugates
Multiple ADC strategies target MSLN and EGFR in mesothelioma. The mAb806-derived ADCs ABT-414, ABBV-221, and ABBV-322 selectively target a tumor-selective EGFR epitope, confirmed in xenograft and patient-derived xenograft (PDX) models. Amatuximab (MORAb-009), a mouse-human chimeric anti-MSLN antibody, reached Phase II trial (MORAb-009-201). High-affinity rabbit monoclonal antibodies YP218 and YP223 target non-Region I MSLN epitopes to circumvent competition with existing Region I-binding agents such as SS1P.
Phase II — MORAb-009-201Anti-MSLN CAR-T Cell Therapy
CAR-T cell therapy targeting MSLN is among the most intensively discussed immunocellular modalities. Clinical trials of anti-MSLN CAR T cells have demonstrated relative safety but only modest efficacy, attributed to the immunosuppressive tumor microenvironment (TME). Both CAR-T and CAR-NK cell platforms are being evaluated against MSLN, alongside bispecific T cell engagers, highlighting convergence of multiple T cell-redirecting strategies on this single antigen. Trials are ongoing in both pleural and peritoneal disease.
Clinical Trials OngoingPD-1/CTLA-4 Inhibitors — Approved & Emerging
Nivolumab plus ipilimumab (anti-PD-1 + anti-CTLA-4) received FDA approval for unresectable MPM in October 2020 based on CheckMate 743, the first new first-line systemic approval in approximately 16 years. PD-(L)1 inhibitors show response rates between 10–29% in Phase II trials; single-agent pembrolizumab was not superior to chemotherapy in the PROMISE-Meso trial. TIGIT blockade combined with PD-1/CTLA-4 inhibition is emerging as a next-generation strategy to overcome resistance in MPM.
FDA Approved — Oct 2020EGFR, AXL & MET Receptor Tyrosine Kinase Targeting
Beyond MSLN, EGFR is a secondary ADC target via the mAb806 platform. AXL and MET co-expression has been characterized as a co-targeting opportunity; IHC and FISH analyses in FFPE MPM samples confirm co-expression, and in vitro sensitivity data support AXL/MET multitarget inhibitors. MET and PI3K/mTOR co-inhibition with ARQ 197 plus NVP-BEZ235 or GDC-0980 is synergistic in mesothelioma cell and xenograft models. AXL knockdown induces wild-type and mutant p53 expression, establishing an AXL-p53 feedback loop.
Preclinical StageKey Quantitative Signals from Patent & Literature Analysis
Data extracted from patent and academic literature signals across MSLN-targeted modalities and checkpoint inhibitor strategies in malignant pleural and peritoneal mesothelioma.
MPM Genomic Alteration Frequency (%)
CDKN2A deletion dominates the MPM genomic landscape at ~70%, followed by NF2/merlin inactivation at ~40%, driving Hippo and mTOR pathway activation as key therapeutic vulnerabilities.
Mesothelioma Pipeline by Development Stage
Checkpoint inhibitors represent the only approved modality; CAR-T and ADC programs remain in clinical and preclinical stages, with oncolytic virus approaches at Phase I.
Median Overall Survival by Treatment Regimen (months)
CheckMate 743 demonstrated nivolumab+ipilimumab achieved 18.1 months median OS versus 14 months for chemotherapy, against a historical standard of 8–14 months on cisplatin/pemetrexed.
Emerging Combination Strategies in MPM
Six combination approaches are converging in MPM, each targeting a distinct barrier — from TME immunosuppression to histology-specific resistance mechanisms.
Strategic Combination Signals Converging in MPM
Retrieved results signal six combination strategies that address distinct mechanistic barriers — from TME immunosuppression to histologic subtype resistance — in malignant pleural and peritoneal mesothelioma.
CAR-T + Checkpoint Inhibitor
The University of Sydney CAR-T review explicitly identifies TME immunosuppression as the primary efficacy barrier for anti-MSLN CAR T cells. Layering checkpoint blockade (anti-CTLA-4, anti-OX40, anti-GITR) onto CAR-T therapy is identified as the most scientifically supported next step. CTLA-4, OX40, and GITR are co-expressed at high levels on tumor-resident regulatory T cells in mesothelioma, and targeting any of these individually generates effective anti-tumor responses in mouse models.
Checkpoint Inhibitor + Oncolytic Virus
The Warsaw review (2022) signals that oncolytic adenoviruses combined with checkpoint inhibitors represent a promising synergistic strategy to overcome immunosuppression in the mesothelioma TME. This approach generates immunogenic cell death and reshapes the TME, potentially sensitizing tumors to subsequent PD-1/CTLA-4 blockade. Earlier Phase I gene therapy trials with intrapleural adenovirus vectors demonstrated safety of intrapleural injection and possible antitumor immune activation.
TIGIT + PD-1/CTLA-4 Triple Blockade
The University of Antwerp review (2022) provides the most recent dataset signal for TIGIT as an additive target to existing PD-1 and CTLA-4 blockade. The authors argue that combined immune checkpoint blockade incorporating TIGIT has the potential to improve upon the modest OS gains seen with nivolumab/ipilimumab alone. TIGIT is described as an inhibitory immunoreceptor on T cells with potential to deepen checkpoint responses in MPM.
CDK4/6 Inhibitors + Standard Chemotherapy
University of Parma data (2022) show that abemaciclib combined with cisplatin/pemetrexed enhances antiproliferative effects through senescence induction in CDKN2A-deleted MPM, with greater antiproliferative effect than chemotherapy alone in MPM cell lines and primary cultures. CDKN2A homozygous deletion occurs in ~70% of MPM cases, supporting a rationale for molecularly stratified enrollment of CDKN2A-deleted patients in clinical trials of CDK4/6 inhibitor combinations.
Key Trial Data and Clinical Development Milestones
Retrieved results contain several explicit clinical signals from Phase I through FDA approval, spanning checkpoint inhibitors, MSLN-targeted antibodies, kinase inhibitors, and gene therapy approaches.
| Trial / Agent | Modality | Stage | Key Outcome Signal |
|---|---|---|---|
| CheckMate 743 (nivolumab + ipilimumab) | Checkpoint ICI | FDA Approved | Median OS 18.1 months vs 14 months for chemotherapy; first new first-line approval in ~16 years (October 2020) |
| CONFIRM trial (nivolumab) | Checkpoint ICI | Phase III | Modest but statistically significant OS benefit for second-line nivolumab versus placebo |
| PROMISE-Meso (pembrolizumab) | Checkpoint ICI | Phase II/III | Single-agent pembrolizumab not superior to chemotherapy (gemcitabine or vinorelbine) in pre-treated patients |
| Anti-MSLN CAR-T clinical trials | CAR-T Cell Therapy | Clinical (Ongoing) | Relative safety demonstrated; modest efficacy attributed to TME immunosuppression |
| MORAb-009-201 (amatuximab) | Anti-MSLN mAb | Phase II | Phase II trial of chimeric anti-MSLN antibody; inhibits MSLN–CA125/MUC16 binding |
| LY3023414 (dual PI3K/mTOR inhibitor) | Kinase Inhibitor | Phase I Expansion | 42-patient expansion cohort; endpoints: safety, PK, ORR in advanced mesothelioma |
| Alisertib (Aurora kinase A inhibitor) | Kinase Inhibitor | Phase II | 26 patients with previously treated unresectable MPM; durable disease control, limited tumor regression; MYC amplification did not correlate with response |
| Ad-NK4 gene therapy (intrapleural) | Gene Therapy | Phase I | Dose escalation 10¹⁰ to 10¹² virus particles; intrapleural injection demonstrated safety; HGF/c-Met pathway targeting |
Track the Full Mesothelioma Clinical Pipeline
Search patent filings, clinical trial signals, and assignee activity for MSLN-targeted programs on PatSnap Eureka.
From MSLN to TIGIT: The Expanding Target Landscape
Mesothelin (MSLN) remains the dominant actionable antigen in MPM for ADC, CAR-T, immunotoxin, and bispecific platforms. The field is moving toward multi-epitope or non-Region-I-targeting antibody strategies — YP218 and YP223 from NCI/NIH Bethesda — to circumvent competition with SS1P and address tumor heterogeneity. MSLN expression does not appear to be independently prognostic in MPM, complicating patient selection, and TME-mediated immunosuppression limits CAR-T efficacy. PatSnap's life sciences intelligence tools can map freedom-to-operate around non-Region-I MSLN epitopes.
TIGIT is identified as the most prominently signaled emerging checkpoint opportunity in this dataset, with the University of Antwerp review (2022) providing the most recent evidence. Developers with PD-1/CTLA-4 assets already in MPM should evaluate TIGIT combination IND strategies. GITR/GITRL is specifically relevant in sarcomatoid MPM — the most therapy-resistant subtype — where cisplatin/irradiation upregulates GITR/GITRL on tumor cells, per Toronto General Hospital/Princess Margaret Cancer Centre data.
Histologic subtype stratification is underutilized. Retrieved results from multiple groups on epithelioid-versus-sarcomatoid behavior suggest that blanket enrollment strategies are inadequate. Clinical trial designs should incorporate histologic and molecular stratification (CDKN2A, NF2, BAP1 status) as enrichment biomarkers. The WIPO global patent database and ClinicalTrials.gov together with PatSnap Eureka enable comprehensive FTO and trial monitoring. Developers can also access raw patent data programmatically via PatSnap's open API.
The absence of retrieved patent filings in the academic dataset signals a gap in commercial IP coverage. Developers and IP strategists evaluating MSLN-ADC or MSLN-CAR-T freedom-to-operate should conduct dedicated patent landscape searches targeting key assignees not captured in academic literature alone. PatSnap customers in oncology use Eureka to close exactly this gap.
Mesothelioma Drug Pipeline — key questions answered
Mesothelin (MSLN) is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein overexpressed in the vast majority of MPM patients, expressed at low levels in normal tissues, making it a favorable tumor-associated antigen (TAA) for targeted intervention. MSLN is expressed at high levels in diseased pleura and peritoneum in the majority of MM patients, and soluble MSLN is FDA-approved as a monitoring biomarker.
Nivolumab plus ipilimumab (anti-PD-1 + anti-CTLA-4) received FDA approval for unresectable MPM in October 2020, based on the CheckMate 743 trial, representing the first new first-line systemic approval in approximately 16 years. The combination achieved median OS of 18.1 months versus 14 months for chemotherapy.
Clinical trials of anti-MSLN CAR T cells have demonstrated relative safety but only modest efficacy, attributed to the immunosuppressive tumor microenvironment (TME). Both CAR-T and CAR-NK cell platforms are being evaluated against MSLN, alongside bispecific T cell engagers, highlighting convergence of multiple T cell-redirecting strategies on this single antigen.
The genomic landscape is defined not by druggable oncogene mutations but by the loss of tumor suppressors: CDKN2A (homozygous deletion in ~70% of cases), NF2/merlin (inactivated in ~40%), BAP1, LATS1/2, and TP53 alterations are the dominant genomic events. These losses activate Hippo and mTOR signaling, creating downstream vulnerabilities.
TIGIT is an emerging checkpoint target identified as a next-generation checkpoint emerging in MPM, with preclinical rationale for combination with anti-PD-1/CTLA-4. TIGIT blockade combined with existing PD-1/CTLA-4 inhibition may overcome resistance in MPM. It is described as an inhibitory immunoreceptor on T cells with potential to deepen checkpoint responses.
Several combination strategies are converging in MPM: CAR-T plus checkpoint inhibitor combinations; checkpoint inhibitor plus oncolytic virus; TIGIT plus PD-1/CTLA-4 triple blockade; CDK4/6 inhibitors plus standard chemotherapy (abemaciclib combined with cisplatin/pemetrexed); AXL/MET co-inhibition plus immunotherapy; and GITR pathway targeting specifically in sarcomatoid MPM.
Still have questions? Let PatSnap Eureka search the mesothelioma patent and literature landscape for you.
Ask Eureka About Mesothelioma PipelineAccelerate Your Mesothelioma Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map MSLN-targeted IP, track checkpoint combination trials, and identify freedom-to-operate opportunities in oncology.
References
- Mesothelin: An Immunotherapeutic Target beyond Solid Tumors — Nemours Children's Hospital, 2022
- Anti-Mesothelin CAR T Cell Therapy for Malignant Mesothelioma — Centenary Institute / University of Sydney, 2021
- Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for MPM — University of Sydney, 2021
- Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma — Olivia Newton-John Cancer Research Institute, Melbourne, 2020
- Amatuximab and Novel Agents Targeting Mesothelin for Solid Tumors — CRO Aviano IRCCS National Cancer Institute, 2017
- New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin — NCI, NIH Bethesda, 2015
- Current Advances in CAR T Cell Therapy for Malignant Mesothelioma — Institute of Cancer Research, London, 2020
- Combination Immune Checkpoint Blockade as an Effective Therapy for Mesothelioma — University of Western Australia, 2018
- Recent Advances of Immune Checkpoint Inhibition and Potential for TIGIT Blockade in MPM — University of Antwerp, 2022
- Advances in Immunotherapy of Malignant Pleural Mesothelioma — Nankai District/Tianjin Review, 2021
- Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma — University of Liège, 2021
- Blocking the GITR-GITRL Pathway to Overcome Resistance in Sarcomatoid MPM — Toronto General Hospital / Princess Margaret Cancer Centre, 2021
- AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 — Brigham and Women's Hospital / Harvard Medical School, 2020
- AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in MPM — Casale Monferrato, Italy, 2022
- MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in MPM — University of Chicago, 2014
- Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects — National Institute of Public Health, Warsaw, 2022
- U.S. Food and Drug Administration (FDA) — Nivolumab+Ipilimumab MPM Approval, October 2020
- World Intellectual Property Organization (WIPO) — Global Patent Database
- ClinicalTrials.gov — Mesothelioma Clinical Trial Registry
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.